Dongwan Bio (东万生物) develops and manufactures medical devices and holds national quality‑system certification for sterile and implantable medical devices. Its product portfolio spans minimally invasive surgical instruments, medical dressings, and medical aesthetics/health products. The company recently received a strategic investment that affected its valuation. The article reports a RMB 10 million strategic investment from Jiangsu Wuzhong. After the investment the company’s post‑money valuation was RMB 500 million with the investor taking a 2% stake. No operating metrics (revenue or users) or future product plans beyond the stated product areas are disclosed in the article.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2023